This database contains 542 studies, archived under the term: "middle aged"
Click here to filter this large number of results.
Multisensory stimulation to improve functional performance in moderate to severe dementia–interim results
Dementia is a growing problem worldwide and interventions to effectively manage and promote function are urgently required. Multisensory environments (MSEs) have been used extensively with people with dementia; however, no studies have been conducted to explore the efficacy of sensory stimulation on functional performance. This study explores to what extent multisensory stimulation influences functional performance […]
Goal-oriented cognitive rehabilitation for people with early-stage Alzheimer disease: a single-blind randomized controlled trial of clinical efficacy
Clare, Linda,
Linden, David E. J.,
Woods, Robert T,
Whitaker, Rhiannon,
Evans, Suzannah J.,
Parkinson, Caroline H.,
van Paasschen, Jorien,
Nelis, Sharon M.,
Hoare, Zoe,
Yuen, Kenneth S. L.,
Rugg, Michael D.
Objectives: To provide evidence regarding the clinical efficacy of cognitive rehabilitation (CR) in early-stage Alzheimer disease (AD).; Design: Single-blind randomized controlled trial comparing CR with relaxation therapy and no treatment.; Setting: Outpatient, community-based setting.; Participants: Sixty-nine individuals (41 women, 28 men; mean age 77.78 years, standard deviation 6.32, range = 56-89) with a diagnosis of […]
Transcultural influences in dementia care: observations from a psychosocial intervention study
Burns, Alistair,
Mittelman, Mary,
Cole, Catherine,
Morris, Julie,
Winter, Jane,
Page, Sean,
Brodaty, Henry
Background: Various models of intervention for caregivers of patients with dementia have been described. There has been little direct comparison of cultural differences between countries and the effect any differences may exert on the outcome of caregiver interventions.; Aims: The aims of the three-country study (USA, Australia and the UK) were to assess whether caregiver […]
Reduction of aggregated Tau in neuronal processes but not in the cell bodies after Abeta42 immunisation in Alzheimer’s disease
Boche, Delphine,
Donald, Jane,
Love, Seth,
Harris, Scott,
Neal, James W.,
Holmes, Clive,
Nicoll, James A. R.
Alzheimer’s disease (AD) pathology is characterised by aggregation in the brain of amyloid-beta (Abeta) peptide and hyperphosphorylated tau (phospho-tau), although how these proteins interact in disease pathogenesis is unclear. Abeta immunisation results in removal of Abeta from the brain but cognitive decline continues to progress, possibly due to persistent phospho-tau. We quantified phospho-tau and Abeta42 […]
A single ascending dose study of bapineuzumab in patients with Alzheimer disease
Black, Ronald S.,
Sperling, Reisa A.,
Safirstein, Beth,
Motter, Ruth N.,
Pallay, Allan,
Nichols, Alice,
Grundman, Michael
The safety, tolerability, and pharmacokinetics (PKs) of bapineuzumab (AAB-001), a humanized monoclonal antibody to amyloid beta, were evaluated in patients with mild-to-moderate Alzheimer disease in a phase 1, randomized, third-party unblinded, placebo-controlled, single ascending dose trial. Thirty patients received bapineuzumab infusion of 0.5, 1.5, or 5 mg/kg or placebo (6 active, 2 placebo for 0.5 […]
Cognitive effects of memantine in postmenopausal women at risk of dementia: a pilot study
Wroolie, T. E.,
Kenna, H. A.,
Williams, K. E.,
Powers, B. N.,
Holcomb, M.,
Lazzeroni, L.,
Rasgon, N. L.
Background: To determine the effects of memantine on cognition in a normal population of postmenopausal women with putative risk factors for Alzheimer’s disease (AD) using a built-in control for the genetic risk factor for AD (apoE-epsilon4 status).; Methods: A prospective, open-label, 6-month pilot medication trial with memantine and follow-up after discontinuance conducted at the Center […]
Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer’s disease
Wilkinson, David,
Schindler, Rachel,
Schwam, Elias,
Waldemar, Gunhild,
Jones, Roy W.,
Gauthier, Serge,
Lopez, Oscar L.,
Cummings, Jeffrey,
Xu, Yikang,
Feldman, Howard H.
Background: Therapeutic endpoints based on reduced clinical worsening represent clinically relevant and realistic goals for patients suffering from progressive neurodegenerative disorders such as Alzheimer’s disease (AD).; Methods: Data from 906 patients (388 receiving placebo; 518 receiving donepezil) with mild-to-moderate AD [Mini-Mental State Examination (MMSE) score 10-27] were pooled from 3 randomized, double-blind placebo-controlled studies. Clinical […]